A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost ...

In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...

The use of biosimilars saved Blue Cross members and employee groups $67 million in 2024 and $80 million in 2025, according to a news release. The savings come amid a cost-cutting push at Blue Cross to ...

After biosimilars launch, it can take years for them to gain a foothold. In 2023, Humira biosimilars made barely a dent in the market, and in 2024 they accounted for only about a quarter of sales, ...

Lowering the prices of prescription drugs has been high on United States President Donald Trump’s agenda since he took office in January. He has taken a number of steps, including striking deals with ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers. The Food and Drug ...

CVS Health Inc. CVS on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to ...

The FDA has decided that biosimilar medications must have unique naming features, distinguishing them from brand-name biologics in a move to improve patient safety, according to a STAT news report. 1.

The global biosimilar contract manufacturing market size was valued at USD 9.22 billion in 2025 and is predicted to hit ...

Trump administration officials pledged Monday that major reforms for biosimilar drug approvals will expand access and lower prices for some of the most expensive drugs on the market. The ...

Zydus Lifesciences launches Anyra, India’s first indigenous biosimilar of Aflibercept, aiming to enhance affordable access to advanced diabetic eye-care treatments and strengthen the country’s ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...